CICC is optimistic about GIANT BIOGENE's improving fundamentals following the approval of its cross-linked recombinant collagen filler as a Class III medical device, which is the first of its kind for neck wrinkles. The company has also launched its first approved medical aesthetics product, showing a positive trend in its cosmetics business. Despite lowering the target price due to valuation pressure in the consumer sector, the broker maintains an Outperform rating and encourages investors to consider buying opportunities.
